- Phenotypic presentation of family members of ATTRv probands and subsequent disease
- 2 penetrance

3

7

9

15

- 4 Luca Fazzini, MD*; Matteo Castrichini, MD*; Yan Li, PhD; Jose De Melo Jr, MD; Marta
- 5 Figueiral, MD; Jenny J. Cao, MB; Eric W. Klee, MD; Christian Cadeddu Dessalvi, MD PhD;
- 6 Martha Grogan, MD; Angela Dispenzieri, MD; Naveen L. Pereira, MD
- 8 *These authors share first authorship
- Affiliations: Department of Cardiovascular Medicine (L.F., M.C., J.DM.Jr, M.F., J.J.C., M.G.,
- 11 N.L.P.); Department of Quantitative Health Science, Division of Clinical Trials and Biostatistics
- 12 (Y.L.); Department of Quantitative Health Science, Division of Computational Biology (E.W.K.);
- Division of Hematology (A.D.), Mayo Clinic, Rochester, MN. Department of Medical Sciences
- and Public Health, University of Cagliari, Cagliari, Italy (L.F, C.C.D.).
- Short title: ATTRv genetic carriers phenotype and outcomes
- 18 Corresponding Author:
- 19 Naveen L. Pereira, MD; Department of Cardiovascular Medicine and Department of Molecular
- 20 Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester,
- 21 MN, 55905. Email: pereira. Twitter @nl_pereira

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Abstract BACKGROUND: Hereditary transthyretin amyloid cardiomyopathy (ATTRv-CM) is being increasingly diagnosed due to enhanced awareness and availability of newer therapeutics. Multiple TTR variants have been described worldwide, but with uncertain disease penetrance. The characteristics and outcomes of "previously undiagnosed" pathogenic-likely pathogenic (P/LP) TTR variant (genotype or G+; cardiac phenotype or P-) carriers are unknown which has important prognostic and therapeutic implications, especially for affected family members. This descriptive study aimed to delineate phenotype and cardiac penetrance in "previously undiagnosed" G+P- family members of ATTRv probands. **METHODS:** Demographic, electrocardiographic (ECG), genetic, and imaging (echocardiography, cardiac technetium-99m pyrophosphate (PYP) and magnetic resonance imaging) data were analyzed. The prediction effect of selected baseline characteristics for ATTRv-CM development was evaluated. Kaplan-Meier and Cox regression methods were used to describe risk and predictors of ATTRv-CM development in family members. **RESULTS:** There were 85 G+P- family members identified. Mean age was 48.5±11.7 years, 39% were male, 18% had a diagnosis of peripheral neuropathy, 15% with a history of carpal tunnel syndrome, and 4% had atrioventricular block at baseline. Of these, 55 patients had followup imaging studies. After a median 6.8-year follow-up, 22% developed ATTR-CM with a 10year estimated risk of 29.5% (95% CI 7.9-46.0). Cardiac penetrance increased with increasing family member's age. Proband's diagnosis age (p=0.0096) and artificial intelligence (AI)-ECG prediction (p=0.0091) were promising baseline predictors of time to ATTRv-CM development.

- **CONCLUSION:** In previously undiagnosed G+P- ATTRv family members, the incidence of
- subsequent CM is high. Predictors for CM development such as proband's diagnosis age and AI-
- determined ECG probability of ATTR-CM require further investigation.

Keywords: transthyretin amyloidosis; phenotype; cardiac; cardiomyopathy

NON-STANDARD ABBREVIATONS AND ACRONYMS

50	AI	artificial intelligence AI
51	ATTR	transthyretin amyloidosis
52	AUC	area under the curve
53	CA	cardiac amyloidosis
54	CI	confidence interval
55	CM	cardiomyopathy
56	CV	cross-validation
57	cMRI	cardiac magnetic resonance
58	ECG	electrocardiographic
59	HR	hazards ratio
60	LV	left ventricular
61	PR	precision recall
62	PYP	pyrophosphate
63		

49

Introduction

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Cardiac amyloidosis (CA) is a well-known cause of heart failure and life-threatening disease. ¹⁻³ Early diagnosis of transthyretin amyloidosis (ATTR) which is a common cause of CA has become especially relevant given recent advances in diagnosis and therapy. 4 Cardiomyopathy (CM) due to ATTR is classified as either wild-type (ATTRwt-CM) or hereditary (ATTRv-CM).⁵ Hereditary ATTR is an autosomal-dominant disease and over 130 TTR variants have been identified that have ethnic and geographical specific distribution. ⁶⁻⁸ Different TTR genotypes are associated with varying phenotypes. 9-11 The correlation between genetic heterogeneity, variability in disease onset, and expression remains an active area of investigation. 12 Genetic testing is recommended in patients diagnosed with ATTR-CM in order to distinguish between wild-type and hereditary disease. 4,13-15 Identifying a pathogenic (P) or likelypathogenic (LP) variant not only enables a diagnosis of ATTRv-CM but also allows for cascade testing in first-degree relatives. ¹⁶ However, managing genotype-positive (G+, carriers of a P or LP variant) phenotype-negative (P-, individuals without evidence of structural heart disease) remains a challenge due to a lack of information on the natural course of the disease and the uncertain cardiac penetrance of these TTR variants. Understanding outcomes and identifying high risk individuals will inform strategies for not only monitoring but also potentially treating TTR genetic (G+P-) carriers. The purpose of this study was to evaluate the natural history, cardiac disease penetrance, and predictors of the development of ATTRv-CM in previously undiagnosed TTR G+P- individuals.

Methods

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Study population The institutional review board of the Mayo Clinic Foundation approved this study which was a single-center, observational, and retrospective study. Among the overall population affected by amyloidosis followed at Mayo Clinic, Rochester, previously undiagnosed family members of probands who were diagnosed with ATTRv and underwent genetic testing were identified from January 1998 to October 2023. Those with P/LP TTR variants without evidence of ATTR-CM at baseline screening (G+P-) were included in the study. P- individuals were defined as those with the absence of echocardiographic evidence of ATTR-CM as previously described¹⁷ and/or negative pyrophosphate (PYP) scintigraphy. Pertinent demographic, clinical, electrocardiographic (ECG), and imaging data closest to the date of genetic testing for these patients were extracted from the electronic medical record. Patients without cardiac imaging at baseline were excluded since the baseline cardiac phenotype could not be determined. The population was divided into two groups based on the development of CM during follow-up. Genetic testing Genomic DNA obtained from submitted samples was enriched for targeted regions using a hybridization-based protocol. Sequence analysis and deletion/duplication testing of the TTR gene were performed. A bi-directional sequence analysis was performed to test for the presence of variants in all coding regions and intron/exon boundaries of the TTR gene. A P/LP variant in the TTR gene was defined as per the American College of Medical Genetics and Genomics (ACMG) standard criteria. 18

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

Cardiomyopathy diagnosis during follow-up The criteria used to diagnose ATTR-CM during follow-up were as follows: 1) Standard previously used echocardiographic criteria (at least two of the following features): 17 normal left ventricular (LV) wall thickness at baseline (≤13mm) that became abnormal during follow-up; normal filling pressures (E/e'\le 8) that became abnormal, normal atria size at baseline that evolved to biatrial enlargement at follow-up; and normal LV global longitudinal strain (<-18%) that subsequently became abnormal. 2) a normal cardiac magnetic resonance (cMRI) scan at baseline which during follow-up demonstrated late gadolinium enhancement and increased extracellular volume consistent with ATTR-CM 3) a negative baseline PYP scintigraphy that became positive during follow-up. Patients were considered not to have developed ATTR-CM if they had any negative follow-up imaging study. Artificial intelligence-enabled electrocardiography A previously developed and validated artificial intelligence (AI) algorithm to diagnose CA was applied to the baseline ECG of the G+P- carriers. 19,20 An AI ECG was considered positive when the probability threshold to detect patients with CA by the Youden index was 0.485 or higher. Statistical analysis Descriptive statistics were used to summarize the characteristics of the study population. Continuous variables are reported as mean (standard deviation, SD) or median (interquartile range [IQR]), and categorical variables are reported as proportions. To evaluate if clinical and echocardiographic characteristics are changed between baseline and follow-up, continuous variables were tested using paired two-sided t-tests, while binary variables were tested if their

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

proportional difference between baseline and follow-up is different from 0. Kaplan-Meier method was used to estimate time-to-event models. Patients without events were censored at the last follow-up. To study the prediction effect of selected baseline characteristics, first we fit the Firth's penalized logistic regressions using the CA development as a dependent variable and the baseline characteristics as independent variables. Next, we aimed to study if there is a synergistic effect of those baseline variables. To retain the sample size of 55, missing values of baseline variables were imputed by median values from corresponding groups (developing or not developing CA). Next, we combine these selected baseline characteristics using Ridge logistic regression. Therefore, the predictor of this Ridge logistic model is the optimal composite score of those baseline variables. We used precision-recall (PR) curve analysis to evaluate the predicting effect of the composite score for CA development. Specifically, 11-fold cross-validation (CV) was used when calculating the area under the curve (AUC), since the score was derived from an estimated model and was needed to protect against overfitting. To improve the estimated performance of the regression model, we repeated the CV procedure 100 times. Univariable Cox proportional hazard models were performed to evaluate the risk of developing overt CA. The Hazard Ratios (HR) and the corresponding 95% Confidence Intervals (CI) were reported. The TRR penetrance on ATTR-CM in different age groups were calculated and their 95% CI were estimated. For all tested hypotheses, the significance level of 0.05 was considered and multiple testing was adjusted by the Bonferroni correction method. All analyses were performed on R version 4.2.2.

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

Results Among the overall ATTR population reviewed (n=1802), 85 carriers were confirmed to have P/LP TTR variants without evidence of CM at the time of genetic testing. Specifically, 80 patients had normal echocardiography and 5 patients had negative PYP scintigraphy alone, 29 patients had both negative echocardiography and PYP scintigraphy. In addition, cMRI at baseline was normal in 4 patients. Baseline characteristics of TTR genotype-positive phenotype-negative individuals Baseline characteristics of the patient population are reported in **Table 1**. The mean age was 48.5±11.7 years, 39% were males, and 91% were White. Comorbidities included spinal stenosis (2%), chronic kidney disease (1%), peripheral neuropathy (18%), and bilateral carpal tunnel syndrome (15%). One patient had undergone permanent pacemaker implantation and 2% had a prior history of syncope. Troponin levels were elevated in 17% of patients, and median NTproBNP in the cohort was normal at 51 pg/ml (IQR 25-88). ECG abnormalities included atrioventricular block (n=3), atrial fibrillation (n=3), low voltage (n=1) and pseudo-infarct pattern (n=3). The median AI-enabled ECG probability of CA was 6.3% (IQR 1.9-19.3), and five patients had an AI-ECG probability above the threshold. None of the patients met the pre-defined echocardiographic criteria for ATTR-CM. Mean septal and posterior wall thickness were 9.3±1.5 and 9.1±1.4 mm respectively with a mean LV end-diastolic volume of 127 ml and LV ejection fraction (LVEF) of 62.6±7.4%. A sensitive indicator of systolic dysfunction, LV global longitudinal strain was slightly reduced (range -15% to -17%) in 11% of patients (n=7/61) but overall mean values were normal at -20.5±2.6%. Left

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

atrial dilation was reported in 10% of subjects with a mean left atrium volume index that was normal at 28 ± 8.5 ml/m². Mean LV filling pressures were not significantly elevated (7.7 ± 2.7). The TTR P/LP variants observed in our population are listed in **Table S1** with Val30Met being the most prevalent (30%), followed by Thr60Ala (28%), Val122Ile (9%), and Ile107Val (7%). Clinical progression in TTR genotype-positive phenotype-negative carriers Among the 85 G+/P- carriers, follow-up clinical and imaging studies were available in 55 patients. Clinical progression in this cohort is described in Table 2. Over a median follow-up period of 6.8 years (IQR 4.1 - 9.7), the risk of developing peripheral neuropathy during followup was 25.5% (95%CI: 8.9, 42.1) as compared to baseline (p=0.004). Specifically, there were an additional 4 patients who developed spinal stenosis, 7 bilateral carpal tunnel syndrome, 5 atrial fibrillation, and 6 syncope during follow-up as compared to baseline. Among the patients (n=24) who were diagnosed with peripheral neuropathy, 15 underwent skin/nerve biopsy, and 2 patients stained positive for amyloid deposition. Small interfering RNA or antisense oligonucleotide therapy was initiated in 12 patients. Cardiac disease penetrance in TTR genotype-positive phenotype-negative carriers Within this group, 53 underwent echocardiography, and 2 patients had a PYP scan alone, 18 had both PYP scintigraphy and echo, and 4 had both cMRI and echo at baseline. During follow-up, 12 (22%) of the 55 patients developed ATTRv-CM. Specifically, 5 patients developed a positive PYP scan, 6 patients were diagnosed based on the change in predefined echocardiography criteria and 1 patient developed cMRI features of CA. The disease-free at 10 years was estimated by the Kaplan-Meier method, and the 10-year risk of developing overt ATTRv-CM was 29.5%

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

(95% CI: 7.9, 46.0, Figure 1). Additionally, cardiac penetrance was assessed among different age groups (Table 3). The penetrance increases as age increases. For the groups ≤ 50 years, 50-60 years, 60-70 years, and > 70 years, there are 11% (95% CI: 3%, 33%), 13% (95% CI: 4%, 38%), 33% (95% CI: 15%, 58%), and 43% (95% CI: 16%, 75%) patients developed ATTRv-CM at the end of the follow-up period, respectively. We also studied cardiac penetrance among different genetic variants. The age distribution is similar among the three most prevalent variants. The median ages at the end of follow-up are 61.0, 60.5, and 59.0 for patients who have Val130Met, Thr60Ala, and Val122Ile variants, respectively. The cardiac penetrance for the three genetic variants are 7% for Val130Met, 33% for Thr60Ala, and 40% for Val122Ile (Table S2). Echocardiographic changes in TTR genotype-positive phenotype-negative carriers Echocardiographic progression in this cohort is described in **Table 2.** Overall, we observed a decrease in LVEF (p=0.014), an increase in septal wall thickness (p=0.037), and an increase in left atrium dilation proportion (p=0.016). Posterior wall thickness, left atrium volume index, bilateral dilation, E/e', and LV GLS did not significantly change. Notably, while at baseline no patients had abnormal wall thickness, 4 patients had abnormal septal wall thickness and 2 patients had abnormal posterior wall thickness during follow-up. In the 12 patients diagnosed with ATTRv-CM (Table 4), the mean LVEF remained normal ($60.3\pm5.3\%$) but was reduced as compared to baseline (p=0.026). There was an increase in the mean septal wall $(9.4 \pm 1.0 \text{ mm} \text{ to } 12.0 \pm 3.3 \text{ mm}, p=0.019)$ and mean posterior wall thickness $(9.8 \pm 1.4 \text{ mm to } 10.9 \pm 3.3 \text{ mm}, p=0.147)$. There was a significant increase in the proportion of ATTRv-CM patients who developed left atrium dilation at follow-up compared to baseline (63.6% vs 9.1%, p=0.008). Notably, 3 developed biatrial dilation during follow-up

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

(p=0.038). Among the 43 patients who did not develop ATTRy-CM by pre-specified criteria (Table S3), there were expectedly no differences between any of the echocardiographic parameters during follow-up as compared to baseline. Predictors of cardiac disease penetrance Baseline characteristics were selected to evaluate for an association with ATTRv-CM development using Firth's penalized logistic regression (Table S4). The proband's age at the time of diagnosis (p-value = 0.0076) and AI-ECG amyloid probability (p-value = 0.0041) were associated with the development of ATTRv-CM. Next, a composite score was calculated that combined all the selected baseline characteristics to evaluate its predictive value for ATTRv-CM development. A Ridge penalized logistic regression was fitted using the disease development as a dependent variable and those baseline characteristics as independent variables. We use the estimated predictor of the fitted model as the composite score. We use the precision-recall analysis to evaluate the prediction performance of the composite score. The estimated AUC under the precision-recall curve from repeated cross-validation was 0.65, which indicated a prediction effect of those variables for ATTRv-CM development. By fitting Cox proportional-hazard regressions, patient's age (HR: 1.09, 95%: 1.01, 1.17, p=0.0246), proband's age of diagnosis (HR: 0.91, 95%: 0.86, 0.98, p=0.0096), NTproBNP (HR: 1.00, 95%: 1.00, 1.01, p=0.0119), scaled AI ECG probability of ATTRv-CM (HR: 1.04, 95% CI: 1.01-1.07, p=0.0091), proband's neurological involvement (HR: 0.23, 95% CI: 0.07-0.83, p=0.0244), and NTproBNP (HR: 1.01, 95% CI: 1.00-1.01, p=0.0187) were associated with the time to ATTR-CM development (Table 5). However, after adjusting for multiple testing these associations were not statistically significant.

Discussion

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

This study, the largest of its kind to describe ATTRv G+/P- carriers, also sheds light on the complex dynamics of cardiac disease penetrance and expressivity in ATTRv, that could help counsel these individuals and may guide informed decision-making regarding the timing of initiating medical therapy. The observed cardiac penetrance rate of 22% over a median 6.8-year follow-up period and its age-dependency, underscores the latency and variable nature of disease manifestation among TTR variant carriers lacking structural evidence of CM at baseline. This study also provides insight into the evolution of cardiac morphology and function as assessed by echocardiography in this genetically diverse group of TTR carriers. Moreover, we observed that the proband's age of diagnosis impacts on disease penetrance in their family members, the older the age at diagnosis of the proband, the lower the probability of developing amyloidosis in family members. We also generated the hypothesis of the potential use of AI-enabled ECG screening at baseline as a non-invasive method for predicting ATTRv-CM penetrance. The AI ECG screening tool offers a promising approach to risk stratification, perhaps enabling a precision medicine approach to attenuate disease progression and improve patient outcomes. Larger studies are needed to validate our exploratory observations. Among genetic cardiomyopathies, the time from being diagnosed with a P/LP to developing the disease is highly variable and often undefined. ²¹⁻²⁴ A Large dataset demonstrated that the frequency of a P/LP TTR variant is not so rare (approximately 1 in 1000 individuals).²⁵ The penetrance of ATTRv manifesting specifically as peripheral neuropathy is also variable in different geographical regions and among families. ²⁶⁻²⁸ Similarly, ATTRv peripheral neuropathy

is also characterized by incomplete cardiac penetrance and variable expressivity. ⁴ A relationship

between age at diagnosis and disease penetrance has been described in this disease, although the underlying age-dependent mechanisms are unknown.²⁹ Male sex has also been associated with an increased risk for peripheral neuropathy disease penetrance in ATTRV30M carriers.²⁶

The natural history of *TTR* variant carriers has been previously described in results of an

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

The natural history of TTR variant carriers has been previously described in results of an observational survey but was based on occurrence of symptoms alone. 30 The outcomes of "asymptomatic" patients (defined as absence of heart failure symptoms) with echocardiographic evidence of ATTR-CM at baseline have also been previously described,³¹ and individuals carriers of a P/LP TTR variant enrolled in the United Kingdom Biobank were found to be at higher risk of heart failure. 25 However, information regarding ATTRv cardiac disease penetrance and expressivity based on cardiac imaging in G+/P- family members is largely unknown.³² In the Atherosclerosis Risk in Communities study, V122I TTR variant Black carriers (n=124) were found to be at an increased risk of incident heart failure as compared to non-carriers over 21.5 years of follow-up.³³ Recently, V122I carriers who were predominately Black were described to have a higher risk of all-cause mortality and heart failure hospitalizations, particularly driven by heart failure with reduced EF, compared to non-carrier controls.³⁴ However, in both these studies whether CA was present at baseline and whether heart failure occurred due to CA or other causes such as coronary artery disease or hypertension is unknown. Furthermore, White subjects were not studied given that the V122I variant is predominantly present in Blacks. Our study addresses these limitations by describing the disease-specific natural history of hereditary ATTR confirmed by imaging in G+P- patients who mostly had variants other than V122I.

It is relevant to highlight that 18% of our overall cohort of family members had a history of clinically diagnosed peripheral neuropathy at baseline and the nerve/skin biopsy, when performed, was most likely to be negative for amyloid deposition. The lack of sensitivity of the

nerve/skin biopsies for amyloid maybe due to the multifocal amyloid deposition process, the early stage of the disease, and the possibility of peripheral neuropathy due to related comorbidities (three patients with negative biopsy had concomitant diabetes mellitus). 35,36 However, the high prevalence and progression of peripheral neuropathy underscores the potential systemic nature of ATTRv amyloidosis and the importance of considering extracardiac manifestations in the risk assessment of these individuals. Despite we were not powered to predict the development of cardiac disease based on extracardiac manifestation, the presence of these extracardiac clinical manifestations should always raise the suspicion of systemic amyloidosis.

Increased LV wall thickness, a classic echocardiographic feature of CA, and a reduction in LVEF were observed but the latter variable remained within normal limits in G+/P- family members LVEF. Sensitive echocardiographic deformation parameters such as myocardial strain have been proposed to detect early involvement of the heart in amyloidosis. However, these values remained within the normal range in our population. Among the seven patients with abnormal global longitudinal strain at baseline, ATTRv-CM was diagnosed only in one case during follow-up. Therefore, global longitudinal strain may not be indicative of subsequent cardiac involvement in our population. Myocardial deformation echocardiographic imaging has primarily been validated in cohorts with some grade of increased myocardial wall thickness and whether this echocardiographic parameter could be useful in the early identification of ATTR-CM in a G+/P- population prior to this study is unknown.³⁷ Moreover, we found that the age at which the proband is diagnosed with ATTRv influences cardiac penetrance in family members. This age-dependent penetrance finding in the proband aligns with the recommendation of

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

beginning disease assessment in family members, 10 years before the affected proband's age of disease onset. 10,38 It is unknown whether and when to initiate newer therapy for ATTR amyloidosis in G+Ppatients representing an unmet need in clinical practice. Our findings suggest that G+Pindividuals with a positive AI-ECG and with an affected proband who was diagnosed at a younger age have a higher probability of developing CM. Patients with high AI-ECG probability may warrant more frequent follow-up with multimodality imaging, and cardiac biopsy may be indicated if imaging is inconclusive especially if patients are symptomatic to consider initiation of therapy. Patient's perspective Returning genetic testing results can be emotionally and logistically challenging for both family members and healthcare providers given the uncertainty in outcomes. Genetic testing results might have a profound impact on individuals and families, highlighting the need for such studies and high-touch methods such as one-on-one genetic counseling. We hope our study with others will help inform not only the clinicians who will encounter these patients but also the patients themselves. Limitations A limitation of our study includes a relatively small sample size which is an inherent limitation of rare diseases, although it is the largest study of TTR P/LP variant carriers with longitudinal cardiac imaging follow-up that provides information on cardiac penetrance of ATTRv in the absence of clinically discernible cardiac disease. Although a longer period of follow-up may

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

have yielded a higher cardiac disease penetrance, this study with a median 6.8-year follow-up period provides a reasonable estimate of disease risk. Furthermore, less than half had PYP scintigraphy, largely driven by the period of the study, which is known to be more sensitive than echocardiograms. Perhaps the cardiac phenotype penetrance might be even higher than what we observed. Larger cohorts will be required to validate our findings such as the use of AI-ECG to identify those at risk for ATTRv-CM development to enable early disease detection and intervention. Conclusion In conclusion, the 10-year estimated risk of ATTRv-CM development in G+P- family members is high at 29.5%, and the most common echocardiographic features that characterize CM development are increased LV wall thickness and left atrial dilation. The risk of developing CM in ATTRv family members appears to be proband age-of-disease dependent and could be predicted by baseline AI ECG. These findings describe the high incidence of CA and the possibility of risk stratifying ATTRv G+P- patients not only to assist in counseling family members but also to provide guidance to clinicians regarding the timing of initiating appropriate but expensive therapy for ATTRv-CM. Further validation of our exploratory analysis results in larger cohorts is needed. **Sources of Funding** Dr. Luca Fazzini received a grant funded by the Italian Society of Cardiology and Bruno Farmaceutici during the research fellowship at Mayo Clinic, Rochester.

Disclosures

359 None.

358

360

361 Supplemental Material

362 Tables S1-S4

References 363 Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and 364 1. infiltrative cardiomyopathies: Part 1 of a 2-Part Series. J Am Coll Cardiol. 2018;71:1130-365 1148. doi: 10.1016/j.jacc.2018.01.016 366 Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and 2. 367 infiltrative cardiomyopathies: Part 2 of a 2-Part Series. J Am Coll Cardiol. 2018;71:1149-368 1166. doi: 10.1016/j.jacc.2018.01.017 369 Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 370 3. 371 2023;118:3517-3535. doi: 10.1093/cvr/cvac119 4. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, 372 Dember LM, Frantz JG, Hershberger RE, Maurer MS, et al. 2023 ACC expert consensus 373 decision pathway on comprehensive multidisciplinary care for the patient with cardiac 374 amyloidosis. J Am Coll Cardiol. 2023;81:1076-1126. doi: doi:10.1016/j.jacc.2022.11.022 375 5. Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, 376 Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and 377 recommendations by the International Society of Amyloidosis (ISA) Nomenclature 378 Committee. Amyloid. 2022;29:213-219. doi: 10.1080/13506129.2022.2147636 379 Mutations in hereditary amyloidosis. [Internet]. 2023. Available from: 380 6. http://www.amyloidosismutations.com/. In. 381 Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-382 7. dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause 383 of significant heart disease in elderly African Americans. Genet Med. 2017;19:733-742. 384 385 doi: https://doi.org/10.1038/gim.2016.200

386	8.	Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional
387		implications. Annu Rev Nutr. 1994;14:495-533. doi:
388		10.1146/annurev.nu.14.070194.002431
389	9.	Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP,
390		Lenihan DJ, Gottlieb SS, Shah SJ, et al. Genotype and phenotype of transthyretin cardiac
391		amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol.
392		2016;68:161-172. doi: 10.1016/j.jacc.2016.03.596
393	10.	Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ,
394		Nair AP, Nativi-Nicolau J, Ruberg FL. Cardiac amyloidosis: Evolving diagnosis and
395		management: A scientific statement from the American Heart Association. Circulation.
396		2020;142:e7-e22. doi: 10.1161/cir.000000000000000092
397	11.	Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M,
398		Grigioni F, Leone O, et al. Disease profile and differential diagnosis of hereditary
399		transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian
400		perspective. Eur Heart J. 2013;34:520-528. doi: 10.1093/eurheartj/ehs123
401	12.	Sekijima Y. Hereditary transthyretin amyloidosis. In: Adam MP, Feldman J, Mirzaa GM,
402		Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, eds. GeneReviews(®).
403		Seattle (WA): University of Washington, Seattle. Copyright © 1993-2024, University of
404		Washington, Seattle. GeneReviews is a registered trademark of the University of
405		Washington, Seattle. All rights reserved.; 1993.
406	13.	Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio
407		ALP, Damy T, Eriksson U, et al. Diagnosis and treatment of cardiac amyloidosis. A

408 position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512-526. doi: 10.1002/ejhf.2140 409 14. Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, Knebel F, Meder 410 411 B, Morbach C, Nagel E, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479-506. 412 doi: 10.1007/s00392-020-01799-3 413 15. Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R, 414 Narayan J, Swiggum E, Venner CP, et al. Canadian Cardiovascular Society/Canadian 415 416 Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol. 2020;36:322-334. doi: 417 10.1016/j.cjca.2019.12.034 418 419 16. Musunuru K, Hershberger RE, Day SM, Klinedinst NJ, Landstrom AP, Parikh VN, Prakash S, Semsarian C, Sturm AC. Genetic testing for inherited cardiovascular diseases: 420 A scientific statement from the American Heart Association. Circ Genom Precis Med. 421 2020;13:e000067. doi: 10.1161/hcg.0000000000000067 422 17. Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, Klein AL, Phelan 423 D, Grogan M. Practical points for echocardiography in cardiac amyloidosis. J Am Soc 424 Echocardiogr. 2022;35:A31-a40. doi: 10.1016/j.echo.2022.06.006 425 18. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon 426 427 E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and 428 Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424. 429 430 doi: 10.1038/gim.2015.30

431 19. Grogan M, Lopez-Jimenez F, Cohen-Shelly M, Dispenzieri A, Attia ZI, Abou Ezzedine OF, Lin G, Kapa S, Borgeson DD, Friedman PA, et al. Artificial intelligence-enhanced 432 electrocardiogram for the early detection of cardiac amyloidosis. Mayo Clin Proc. 433 434 2021;96:2768-2778. doi: 10.1016/j.mayocp.2021.04.023 Harmon DM, Mangold K, Suarez AB, Scott CG, Murphree DH, Malik A, Attia ZI, 20. 435 Lopez-Jimenez F, Friedman PA, Dispenzieri A, et al. Postdevelopment performance and 436 validation of the artificial intelligence-enhanced electrocardiogram for detection of 437 cardiac amyloidosis. JACC: Advances. 2023;2:100612. doi: 438 439 doi:10.1016/j.jacadv.2023.100612 Topriceanu CC, Pereira AC, Moon JC, Captur G, Ho CY. Meta-analysis of penetrance 21. 440 and systematic review on transition to disease in genetic hypertrophic cardiomyopathy. 441 Circulation. 2024;149:107-123. doi: 10.1161/circulationaha.123.065987 442 22. Shah RA, Asatryan B, Sharaf Dabbagh G, Aung N, Khanji MY, Lopes LR, van 443 Duijvenboden S, Holmes A, Muser D, Landstrom AP, et al. Frequency, penetrance, and 444 variable expressivity of dilated cardiomyopathy-associated putative pathogenic gene 445 variants in UK Biobank participants. Circulation. 2022;146:110-124. doi: 446 10.1161/circulationaha.121.058143 447 McGurk KA, Zhang X, Theotokis P, Thomson K, Harper A, Buchan RJ, Mazaika E, 23. 448 Ormondroyd E, Wright WT, Macaya D, et al. The penetrance of rare variants in 449 450 cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for secondary findings. Am J Hum Genet. 2023;110:1482-1495. doi: 451 10.1016/j.ajhg.2023.08.003 452

453 24. Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: practical implications for heart failure management. Nat Rev Cardiol. 2020;17:286-297. doi: 454 10.1038/s41569-019-0284-0 455 25. Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S, Petersen SE, 456 Munroe PB, Elliott PM, Lopes LR. Prevalence, cardiac phenotype, and outcomes of 457 458 transthyretin variants in the UK Biobank population. JAMA Cardiol. 2024. doi: 10.1001/jamacardio.2024.2190 459 26. Gorram F, Olsson M, Alarcon F, Nuel G, Anan I, Planté-Bordeneuve V. New data on the 460 461 genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid. 2021;28:84-90. doi: 10.1080/13506129.2020.1841623 462 27. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. 463 Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the 464 Swedish population. *Amyloid*. 2008;15:181-186. doi: 10.1080/13506120802193720 465 28. Planté-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, 466 Said G, Bonaïti-Pellié C. Genetic study of transthyretin amyloid neuropathies: carrier 467 risks among French and Portuguese families. J Med Genet. 2003;40:e120. doi: 468 10.1136/jmg.40.11.e120 469 29. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. *Lancet Neurol*. 470 2011;10:1086-1097. doi: 10.1016/s1474-4422(11)70246-0 471 472 30. Coelho T, Conceição I, Waddington-Cruz M, Keohane D, Sultan MB, Chapman D, Amass L. A natural history analysis of asymptomatic TTR gene carriers as they develop 473 symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes 474 475 Survey (THAOS). Amyloid. 2022;29:228-236. doi: 10.1080/13506129.2022.2070470

476 31. Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, AbouEzzeddine OF, Mussinelli R, Gagliardi C, Kharoubi M, et al. Prognosis of 477 transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol. 478 2022;4:442-454. doi: 10.1016/j.jaccao.2022.07.007 479 Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, 32. 480 Alexander K, Masri A. Prevalence and outcomes of p.Val142Ile TTR amyloidosis 481 cardiomyopathy: A systematic review. Circ Genom Precis Med. 2021;14:e003356. doi: 482 doi:10.1161/CIRCGEN.121.003356 483 Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, 484 33. Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant 485 in elderly Black Americans. New Engl J Med. 2015;372:21-29. doi: 486 10.1056/NEJMoa1404852 487 Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, Khan SS, 488 34. Rich SS, Mosley TH, Levitan EB, et al. Cardiovascular burden of the V142I transthyretin 489 variant. JAMA. 2024;331:1824-1833. doi: 10.1001/jama.2024.4467 490 35. Freeman R, Gonzalez-Duarte A, Barroso F, Campagnolo M, Rajan S, Garcia J, Kim JY, 491 Wang N, Orellana L, Gibbons C. Cutaneous amyloid is a biomarker in early ATTRV 492 neuropathy and progresses across disease stages. Ann Clin Transl Neurol. 2022;9:1370-493 1383. doi: 10.1002/acn3.51636 494 495 36. Said G. Indications and usefulness of nerve biopsy. Arch Neurol. 2002;59:1532-1535. doi: 10.1001/archneur.59.10.1532 496

Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J,

Kuznetsova T, Voigt JU. Echo parameters for differential diagnosis in cardiac

497

498

37.

amyloidosis: A head-to-head comparison of deformation and nondeformation parameters.

*Circ Cardiovasc Imaging. 2017;10:e005588. doi: 10.1161/circimaging.116.005588

38. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol. 2019;73:2872-2891. doi: 10.1016/j.jacc.2019.04.003

Table 1. Baseline characteristics of the overall G+/P- ATTRv cohort.

507

	Overall
	(n=85)
-	
Age (years)	48.5 (11.7)
Male sex n (%)	33 (39)
White n (%)	77 (91)
Proband`s cardiac involvement n (%)	47 (55)
Proband`s neurological involvement n (%)	51 (60)
Proband`s organ involvement unknown n (%)	10 (12)
First-degree relatives, n (%)	63 (74)
Second-degree relatives, n (%)	22 (26)
Blood test	
$\frac{\text{Blood test}}{\text{WBC } (\text{x}10^3/\mu\text{L})^{\text{a}}}$	61(5160)
	6.1 (5.1-6.9)
Hb (g/dL)	13.9 (1.4)
$\frac{\text{PLT} (\text{x}10^3/\text{µL})^{\text{a}}}{\text{Prince}}$	231.0 (208.0-251.5)
Positive troponin n (%)	12 (17)
NTproBNP (pg/ml) ^a	51.0 (25.0-88.0)
Comorbidities	
Spinal stenosis n (%)	2 (2)
Peripheral neuropathy n (%)	15 (18)
CKD n (%)	1(1)
Bilateral carpal tunnel syndrome n (%)	13 (15)
Pacemaker n (%)	1(1)
Syncope n (%)	2 (2)
ECG	
	2 (4)
Atrial fibrillation n (%)	3 (4)
AVB n (%)	3 (4)
Low voltage n (%)	1(1)
Pseudo-infarct pattern n (%)	3 (4)
AI amyloid probability above threshold n (%)	5 (6)
Imaging	
Echocardiography n (%)	80 (94)
PYP scintigraphy n (%)	34 (40)
Cardiac Magnetic Resonance n (%)	4 (5)
Baseline Echocardiographic Features	
LVEF	62 6 (7 1)
	62.6 (7.4)
Posterior wall thickness (mm)	9.1 (1.4)
Septal wall thickness (mm)	9.3 (1.5)

LVEDV (ml)	127 (25.7)
LA dilation n (%)	7 (10)
Biatrial dilation n (%)	2 (3)
LAVI (ml/m2)	28 (8.5)
RV dysfunction n (%)	2 (3)
RVSP (mmHg)	27.5 (5.2)
E/e`*	7.7 (2.7)
LV GLS (%)	-20.5 (2.6)
Gene variants	
Val30Met n (%)	25 (29)
Thr60Ala n (%)	24 (28)
Val122Ile n (%)	8 (9)
Ile107Val n (%)	6 (7)
Other n (%)	22 (26)

AI: artificial intelligence. AVB: atrioventricular block. CKD: chronic kidney disease. GLS: left ventricular global longitudinal strain. LVEDV: left ventricle end-diastolic volume. LVEF: left ventricle ejection fraction. LA: left atrium. LAVI: left atrium volume index. PYP: pyrophosphates. RV: right ventricle. RVSP: right ventricle systolic pressure.

- *: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not available, the only septal E/e` was reported.
- Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.
- **a**: Data represent median (1st quantile, 3rd quantile).

Table 2. Clinical and echocardiographic characteristics in G+/P- ATTRv carriers who had follow-

522 up data available (n=55).

521

	Baseline	Follow-up	Difference	p-value#
Comorbidities				_
Spinal stenosis n (%)	2 (3.6)	6 (10.9)	7.3 (-2.3, 16.9)	0.142
Peripheral neuropathy n (%)	10 (18.2)	24 (43.6)	25.5 (8.9, 42.1)	0.004
CKD n (%)	1 (1.8)	6 (10.9)	9.1 (0.1, 18.1)	0.051
Bilateral carpal tunnel syndrome n (%)	9 (16.4)	16 (29.1)	12.7 (-2.8, 28.2)	0.111
Atrial fibrilation n (%)	3 (5.5)	8 (14.5)	9.1 (-2, 20.2)	0.112
Pacemaker n (%)	1 (1.8)	1 (1.8)	-	-
Syncope n (%)	2 (3.6)	8 (14.5)	10.9 (0.4, 21.5)	0.047
Echocardiography				
LVEF	63.3 (4.3)	61.2 (3.6)	-2 (-3.6, -0.4)	0.014
Septal wall thickness (mm)	9.4 (1.6)	10.2 (2.4)	0.7 (0, 1.3)	0.037
Abnormal septal wall thickness n (%)	0 (0)	4 (8.7)	8.7 (0.6, 16.8)	0.035
Posterior wall thickness (mm)	9.3 (1.5)	9.2 (2.2)	0 (-0.5, 0.6)	0.853
Abnormal posterior wall thickness n (%)	0 (0)	2 (4.5)	4.5 (-1.6, 10.7)	0.128
Left atrium volume index (ml/m2)	28.5 (9.6)	29.2 (6.8)	1.1 (-2.3, 4.5)	0.518
Left atrium dilation n (%)	5 (10.2)	14 (29.8)	19.6 (4, 35.2)	0.016
Biatrial dilation n (%)	2 (4.3)	4 (8.9)	4.6 (-5.5, 14.8)	0.368
E/e`*	7.4 (2.2)	7.2 (2.4)	0.3 (-0.6, 1.1)	0.558
LV GLS (%)	-19.8 (2.7)	-20.4 (3)	-0.6 (-1.5, 0.3)	0.205
523	_			

- 524 CKD: chronic kidney disease. GLS: left ventricular global longitudinal strain. LV: left ventricular. LVEF:
- 525 left ventricle ejection fraction.
- *: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not
- available, the only septal E/e' was reported.
- Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.
- The proportional difference (95% confidence interval, CI) for binary variables or the mean difference
- 530 (95% CI) for continuous variables are reported in the column named by "Difference".
- For binary variables, the proportional difference between follow up and baseline levels was tested if it is
- different from 0. For continuous variables, paired t test was used to test if the variable's mean is different
- between baseline and follow up time. Tow-sided tests were used.
- #: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account
- for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/16
- 536 = 0.00313.

Table 3. Estimated penetrance for developing cardiac amyloidosis based on various G+/P- ATTRv carrier age groups.

Age Groups*	Total No. of Patients	Penetrance	95% CI
<= 50 years	18	0.11	(0.03, 0.33)
50-60 years	15	0.13	(0.04, 0.38)
60-70 years	15	0.33	(0.15, 0.58)
>= 70 years	7	0.43	(0.16, 0.75)

^{*:} the age at the cardiac amyloidosis diagnosis or at the last follow-up.

Table 4. Differences between echocardiographic characteristics at baseline and last follow-up among G+/P-ATTRv carriers who developed CA (n=12).

542

543

544

545

546

547

551

552553

554

555556

557

558

	Baseline	At CA diagnosis	Difference	p-value#
LVEF	65.2 (3.3)	60.3 (5.3)	-5.2 (-9.6, -0.8)	0.026
Septal wall thickness (mm)	9.4 (1)	12 (3.3)	2.7 (0.6, 4.8)	0.019
Abnormal septal wall thickness n (%)	0 (0)	4 (36.4)	36.4 (7.9, 64.8)	0.034
Posterior wall thickness (mm)	9.8 (1.4)	10.9 (3.3)	1.4 (-0.6, 3.4)	0.147
Abnormal posterior wall thickness n (%)	0 (0)	2 (22.2)	22.2 (-4.9, 49.4)	0.099
Left atrium volume index (ml/m2)	28.2 (10.6)	33.3 (8.1)	6.3 (-3.5, 16.1)	0.173
Left atrium dilation n (%)	1 (9.1)	7 (63.6)	54.5 (21.4, 87.7)	0.008
Biatrial dilation n (%)	0 (0)	3 (33.3)	33.3 (2.5, 64.1)	0.038
E/e`*	8.1 (3.6)	8.6 (4)	2.2 (-1.4, 5.8)	0.198
LV GLS (%)	-19.3 (3.2)	-18 (4.1)	0 (-3.4, 3.5)	0.966

GLS: left ventricular global longitudinal strain. LV: left ventricular. LVEF: left ventricle ejection fraction.

*: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not available, the only septal E/e` was reported.

Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

The proportional difference (95% confidence interval, CI) for binary variables or the mean difference (95% CI) for continuous variables are reported in the column named by "Difference".

For binary variables, the proportional difference between follow up and baseline levels was tested if it is different from 0. For continuous variables, paired t test was used to test if the variable's mean is different between baseline and follow up time. Tow-sided tests were used.

#: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/10 = 0.005.

Table 5. Association between baseline characteristics and ATTRv-CM development risk.

	Estimated HR	95% CI	p-value#
Age (years)	1.09	(1.01, 1.17)	0.0246
Male sex	2.20	(0.66, 7.33)	0.1999
Proband's age	0.91	(0.86, 0.98)	0.0096
Proband`s cardiac involvement	2.56	(0.74, 8.80)	0.1356
Proband`s neuro involvement	0.23	(0.07, 0.83)	0.0244
NTproBNP (pg/ml)	1.01	(1.00, 1.01)	0.0187
Peripheral neuropathy	0.89	(0.24, 3.36)	0.8674
Bilateral carpal tunnel syndrome	3.78	(0.89, 15.99)	0.0705
AI amyloid probability at ECG	1.04	(1.01, 1.07)	0.0091
LVEF	1.01	(0.89, 1.15)	0.8778
Posterior wall thickness (mm)	1.41	(0.86, 2.30)	0.1736
Septal wall thickness (mm)	1.08	(0.70, 1.66)	0.7393
Val30Met	0.20	(0.02, 1.56)	0.1230
Thr60Ala	1.68	(0.54, 5.23)	0.3742
Val122Ile	4.96	(0.91, 27.15)	0.0648

AI: artificial intelligent; ECG: electrocardiogram; LVEF: left ventricle ejection fraction.

#: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/15 = 0.003.

Figure 1. Kaplan-Meier curve showing the 10-year risk of developing overt ATTRv-CM (29.5%, 95% CI: 7.9, 46.0).

